Home » Newsletters » BioWorld Science

BioWorld Science

March 5, 2020

View Archived Issues

Epigenetic therapy disrupts premetastatic microenvironment

FDA clears IND application for AIM-001

First patient dosed in phase I study of HLX-55

Nascent Biotech to evaluate the potential of pritumumab as therapy for COVID-19

Phase III data reported from ESCAPE-NA1 study of nerinetide

FGL1 as a novel therapeutic target in obesity

Forma Therapeutics patents HDAC6 inhibitors

Gudui Biopharma Technology identifies new compounds for stroke

Merck & Co. divulges new IDO1 inhibitors

Caloric restriction prevents negative aging effects in rats

Lead Discovery Center synthesizes HER2 and EGFR inhibitors

Target Biopharmaceutical Technology Shenzhen discloses SN-38 derivatives

SMARCA4 expression is lost in sinonasal teratocarcinosarcoma

miR-10a-5p found to be a therapeutic target for treating NSCLC

Bayer initiates phase II study of BAY-2586116 in obstructive sleep apnea

Takeda begins development of anti-SARS-CoV-2 polyclonal H-IG

New phase I trial studies imaging agent I-124 M5A to detect liver metastases from colorectal cancer

Identification of orally available PI3Kdelta inhibitors unveils Vps34 as a key selectivity target

PTP1B has a key role in memory impairment and neurodegeneration in a mouse model of familial AD

ZEB1 is associated with poorer survival in peritoneal malignant mesothelioma

EpiVax collaborates with University of Georgia and Generex to develop COVID-19 vaccines

Genentech opening enrollment in phase I study of XmAb-24306 for advanced solid tumors